Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Technology appraisal guidance
Reference number: TA589
Published:
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, the deadline for submissions is now expected late October 2017.